Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PureTech Health: Applying Deep Thinking And Business Acumen

Executive Summary

Targeting the age-dependent decline in immune function is the aim of a new PureTech Health subsidiary, resTORbio, that has licensed two clinical-stage mTORC1 inhibitors from Novartis.

Advertisement

Related Content

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed
Deal Watch: BioLineRx, Ono, Vedantra Ink Separate Cancer Immunotherapy Pacts
Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO
BioNotebook: Former Sanofi CEO Viehbacher joins PureTech board; three venture financings, four deals and a dropped drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel